摘要 |
Hoechst Aktiengesellschaft HOE 93/F 249 Dr. v.F./St of the disclosure Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containg them. Diacyl-substituted guanidines of the formula I <IMG> I are described where X(1) and X(2) <IMG> T1 is zero, 1, 2, 3 or 4, R(A) and R(B) are hydrogen, Hal, CN, OR(106), (O)(cyclo) (fluoro)alkyl, NR(107)R(108), phenyl or benzyl, or X(1) and X(2) are <IMG> T2a and T2b are, independently of each other, zero, 1 or 2, where the double bond can be in the E or Z configuration; or X(1) and X(2) are <IMG> as are the pharmaceutically tolerated salts thereof. They are outstandingly suitable for use as antiarrhythmic pharmaceuticals possessing a cardioprotective component for the prophylaxis and treatment of infarction and for the treatment of angina pectoris, in connection with which they also inhibit or strongly reduce, in a preventive manner, the pathophysiological processes associated with the genesis of ischemically induced damage, in particular associated with the elicitation of ischemically induced cardiac arrhythmias. On account of their protective effects against pathological hypoxia and ischemic situations, the compounds of the formula I according to the invention can, as a consequence of inhibiting the cellular Na+/H+ exchange mechanism, be used as pharmaceuticals for treating all acute or chronic damage elicited by ischemia, or diseases induced primarily or secondarily thereby.
|
申请人 |
HOECHST AKTIENGESELLSCHAFT |
发明人 |
KLEEMANN, HEINZ-WERNER;LANG, HANS-JOCHEN;WEICHERT, ANDREAS;CRAUSE, PETER;SCHOLZ, WOLFGANG;ALBUS, UDO;SCHWARK, JAN-ROBERT |